GE HealthCare Partners with Diagnoly to Integrate AI-Based Fetal Ultrasound Analysis

GE HealthCare has partnered with Diagnoly, a Lyon, France-based DeepTech company specializing in AI-driven prenatal screening, to promote the use of artificial intelligence in fetal ultrasound examinations. According to the agreement, Diagnoly’s Fetoly solution will be integrated into GE HealthCare’s Voluson women’s health ultrasound systems and made available through the Voluson Solution Store in the United States and Europe.

Ultrasound plays a vital role throughout pregnancy by offering clinicians insights into fetal growth, development, and potential congenital conditions. However, factors such as fetal movement, patient anatomy, and operator variability can affect image quality and exam consistency. GE HealthCare stated that integrating AI-based tools is intended to support more standardized examinations and reduce variability during routine fetal assessments.

Fetoly is a real-time, FDA 510(k)-cleared, and CE-marked AI solution designed to deliver comprehensive, standardized fetal ultrasound examinations aligned with the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guidelines. It aims to provide clinicians with AI-powered diagnostic support for fetal heart and brain analysis, while also verifying exam completeness and quality criteria in real time. This capability is expected to enhance the Voluson portfolio further, supporting clinicians in delivering optimal care.

“AI is redefining what’s possible in healthcare, and GE HealthCare is at the forefront of this movement, as an industry leader bringing AI-powered innovations to clinicians,” said Gerald Seifriedsberger, General Manager, Women’s Health Ultrasound at GE HealthCare. He noted that the collaboration expands the company’s ability to embed AI-based screening support directly into Voluson ultrasound systems.

Ivan Voznyuk, Co-Founder and CEO of Diagnoly, highlighted the complexity of obstetric ultrasound and the potential role of AI in addressing detection gaps. “As a result, up to 50% of fetal abnormalities remain undetected during pregnancy,” he said. “The integration of Fetoly into trusted Voluson ultrasound systems reflects our shared commitment to supporting clinicians in real time.”